سعر اميونوهوبس 180وحدة دولية /مل فيال 2026

Immunohbs 180 IU/ml: human hepatitis B immunoglobulin solution for intramuscular injection, single vial; used for passive immunoprophylaxis against hepatitis B.

• Prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B-induced liver failure (with an appropriate antiviral agent where appropriate).AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci
• Hepatitis B immunoprophylaxis: after accidental exposure in non-immunised people; in haemodialysis patients until vaccination is effective; in newborns of hepatitis B carrier mothers; and in vaccine non-responders needing continued protection.AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci

• Local injection-site reactions (swelling, soreness, redness, induration, warmth, itching, bruising, rash) may occur frequently. Occasionally: tachycardia, chills, headache, dizziness, fever, vomiting, nausea, allergic reactions, arthralgia, low blood pressure and moderate back pain; rarely sudden fall in blood pressure and, in isolated cases, anaphylactic shock.International label, same formulation · AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci

• Hypersensitivity to human immunoglobulins or to any excipient (glycine, sodium chloride); must not be given intravascularly; must not be given intramuscularly in severe thrombocytopenia or other haemostasis disorders.International label, same formulation · AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci

• True hypersensitivity reactions are rare; contains small amounts of IgA, so IgA-deficient patients may develop anti-IgA antibodies and anaphylaxis; rarely a fall in blood pressure with anaphylactic reaction can occur even after previously tolerated treatment. Stop the injection immediately if allergic reactions occur.International label, same formulation · AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci
• Arterial and venous thromboembolic events have been associated with immunoglobulins; ensure adequate hydration and use caution in patients with pre-existing thrombotic risk factors.International label, same formulation · AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci
• No benefit if the recipient is an HBsAg carrier. Passively transferred antibodies may give falsely positive serological tests, including the direct antiglobulin (Coombs) test.International label, same formulation · AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci

• Live attenuated virus vaccines (measles, mumps, rubella, varicella)Immunoglobulin may impair the response to live attenuated virus vaccines for up to 3 months; wait at least 3 months after this product before such vaccination. If given within 3-4 weeks after a live vaccine, revaccinate 3 months later.AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci

• Safety in human pregnancy has not been established in controlled clinical trials, so it should be given with caution to pregnant women; clinical experience with immunoglobulins suggests no harmful effects on the course of pregnancy, the fetus or the newborn.International label, same formulation · AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci
• Safety during breastfeeding has not been established in controlled trials, so give with caution; immunoglobulins are excreted in milk and may help protect the newborn from pathogens entering via mucosa.International label, same formulation · AIFA (Agenzia Italiana del Farmaco) - Banca Dati Farmaci

• Human hepatitis B immunoglobulin (anti-HBs): Mainly IgG with a high content of antibodies against hepatitis B surface antigen (anti-HBs), providing passive immunity; bioavailable after 2-3 days with a half-life of about 3-4 weeks.